Promising Agents Could Alter the Treatment Paradigm in Metastatic TNBC

Jason Harris
Published: Monday, Oct 15, 2018
Joyce A. O’Shaughnessy, MD

Joyce A. O’Shaughnessy, MD

Since triple-negative breast cancer (TNBC) is resistant to multiple therapies, physicians have little flexibility for treatment options. However, anticipation is building for potential alternatives. “Right now, for TNBC, chemotherapy is our only option,” said Joyce A. O’Shaughnessy, MD, co-chair of Breast Cancer Research and the chair of Breast Cancer Prevention Research at Baylor- Sammons Cancer Center in Dallas, Texas. “That’s about to change very soon with the likely availability of atezolizumab [Tecentriq].”

East, held by Physicians’ Education Resource® in New York, O’Shaughnessy walked her audience through the most recent findings and ongoing research in the field, focusing on agents inhibiting the PI3K/AKT signaling pathway and the ADC sacituzumab govitecan.


The PI3K/AKT/mTOR signaling pathway is frequently activated in TNBC. Furthermore, deficient PTEN expression is often found in TNBC and is associated with a higher degree of PI3K pathway activation.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication